Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT03145181Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of teclistamab in multiple myeloma (MM) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days and Number of Participants With Adverse Events. Started May 2017; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03145181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145181.